Curexo Showcases FDA-Cleared CUVIS-joint Robotic Surgery Systems at AAHKS 2026 in USA

November 9, 2026 Dr. Michael Lee – Health Editor Health

Reaching an accumulated milestone of approximately 43,000 procedures across more than nine countries, medical robotics firm Curexo showcased its automated joint replacement technology at the 2026 Annual Meeting of the American Association of Hip and Knee Surgeons in Dallas.

    Key Clinical Takeaways:

  • Curexo displayed the CUVIS-joint and CUVIS-joint THA systems at the AAHKS 2026 meeting in Dallas between November 5 and 8.
  • The presentation follows the US Food and Drug Administration granting 510(k) clearance to the CUVIS-joint system in March.
  • The technology utilizes patient CT scans to build three-dimensional surgical plans for automated bone resection.

Exhibition at AAHKS 2026

The medical robotics company displayed two surgical robot systems at the event held from November 5 to 8. The annual gathering draws orthopedic specialists and clinicians from across North America.

Day 1 Recap Video from the 2026 AAHKS Annual Meeting

This appearance marked the first large-scale exhibition of the CUVIS-joint system to American orthopedic surgeons since the company secured FDA 510(k) clearance earlier this year. Curexo aims to expand its network among local medical professionals and initiate full-scale entry into the US market.

CUVIS-Joint Uses CT Data for Automated Bone Resection

The CUVIS-joint system relies on patient computed tomography data to establish a three-dimensional surgical blueprint, executing bone resection through an automated process. The platform features an open design that remains unattached to any specific implant, allowing compatibility with various devices for patient-specific procedures.

Day 2 Recap Video from the 2026 AAHKS Annual Meeting

Regulatory authorizations for the system include South Korea’s Ministry of Food and Drug Safety approval in 2020, followed by Japan’s Pharmaceuticals and Medical Devices Agency clearance and European CE MDR certification. The technology is currently deployed in more than nine countries, accounting for approximately 43,000 accumulated clinical procedures.

Hip Replacement System Development

Alongside the knee system, Curexo featured the CUVIS-joint THA for total hip arthroplasty, which uses pre-surgical 3D planning to minimize implant placement errors and leg length discrepancies.

North American and European regulatory approvals for the hip arthroplasty system are currently underway.

A Curexo representative stated, “This AAHKS participation was a venue to fully showcase the technological prowess and competitiveness of the CUVIS-joint to the US market following the acquisition of FDA 510(k) clearance,” The representative added that the firm intends to leverage its accumulated clinical record and automation technology to build out product competitiveness spanning from knees to hips and secure tangible business performance in the US.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

Related reading